GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Orgenesis ORGS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.35

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Orgenesis

Its shares trade under the ticker ORGS. It has been listed since 1 July 2010. In the fiscal year to 31 December 2024, it reported revenue of $1.0m and a net loss of $48.2m. At that date it held total assets of $1.4m and shareholders' equity of −$37.5m.

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland. The company went IPO on 2010-07-01. The firm is developing, manufacturing and processing of technologies and services in the cell and gene therapy industry. The firm operates a point-of-care (POCare) cell therapy platform (POC). The POC platform develops Advanced Therapy Medicinal Products (ATMPs) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patient. The POC platform include a multitude of cell therapies, including autoimmune, oncologic, neurologic and metabolic diseases and other indications.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
1 Jul 2010
Employees
77
Head office
20271 GOLDENROD LANE, GERMANTOWN, MD, 20876
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Ms. Vered CaplanChairperson of the Board of Directors, Chief Executive Officer, since 2012$341,384
  • Dr. Itzhak ViderIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
26
Environment
28
Social
39
Governance
13
Women in the workforce
55%
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Orgenesis employs 77 full-time employees in Germantown, Maryland.
  • Orgenesis operates a point-of-care cell therapy platform (POC) for ATMPs.
  • Orgenesis collaborates with pre-clinical biopharmaceutical companies for ATMP development.

Weaknesses

  • Orgenesis has 77 employees, which is fewer than industry standards.
  • Orgenesis IPO was on 1 July 2010, a decade ago.
  • Orgenesis focuses on cell and gene therapy, a high-risk sector.

Opportunities

  • Orgenesis can expand its POC platform to include neurologic diseases.
  • Orgenesis can collaborate with healthcare institutes for new ATMPs.
  • Orgenesis can develop metabolic disease therapies using its platform.

Threats

  • Orgenesis faces competition from other biotech firms in cell therapy.
  • Orgenesis must navigate regulatory challenges in the ATMP industry.
  • Orgenesis must manage high costs associated with gene therapy development.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.